The Greek Health Care Reform After Troika's Involvement: The Potential Impact on Global Pricing and Access Strategy

Abstract

A429is overlap in the criteria to qualify for funding. Many countries consider drugs for additional funding when a drug can be used in more than one indication and cannot be grouped to a specific DRG. Other criteria identified relate to, for example, drug prices and indications. Some countries grant additional reimbursement for drugs prior to assessment by a national reimbursement process, while others only grant additional reimbursement after the drug has been available for a certain period of time and funding decisions are based on historical data. In most countries, additional reimbursement is considered annually. Hospitals and expert groups can suggest additional reimbursement for expensive drugs to the responsible authority. ConClusions: Many countries have adapted to the need for additional funding for expensive drugs, and have established systems to grant this funding to hospitals. There are differences in criteria to qualify for, and timelines for receiving, additional funding after drugs are launched.